Copper coordination
The GHK sequence forms a high-affinity complex with copper, creating a biologically active carrier rather than acting as an unbound mineral salt.
NXP / 06
Research profile
GHK-CU
50MGCopper-binding tripeptide research material
GHK-Cu is the copper complex of the naturally occurring tripeptide glycyl-L-histidyl-L-lysine. Its research value comes from the way the peptide binds and delivers copper within systems involved in extracellular-matrix turnover and tissue remodelling.
Scientific context
What it does.
GHK-Cu is studied for effects on fibroblast activity, collagen and glycosaminoglycan accumulation, oxidative balance, inflammatory signalling and angiogenesis. Evidence is strongest in laboratory and preclinical models; injectable human safety data remain limited.
Mechanism map
How the research
model works.
Matrix signalling
Experimental models report changes in fibroblast behaviour and accumulation of collagen, protein and glycosaminoglycans.
Remodelling response
Copper-dependent enzymes and angiogenic signalling make GHK-Cu useful for studying repair-associated extracellular-matrix pathways.
Study design
Research pairing
options.
These are experimental design concepts—not recommendations for human use, co-administration or dosing.
Wolverine 10MG
Can support a multi-pathway design comparing matrix/copper signalling with BPC-157 and TB-500-related repair pathways.
Angiogenesis and repair endpoints overlap, so include single-agent arms to preserve attribution.NAD+ 500MG
Provides a complementary redox and cellular-energy axis for oxidative-stress or remodelling models.
Validate chemical compatibility and assay interference before any combined preparation.Unstacked control
GHK-Cu alone provides the clearest read on copper-dependent matrix and fibroblast responses.
Always include vehicle and copper-control conditions where scientifically appropriate.Interpretation controls
Important
limitations.
- Do not infer injectable safety from topical, in-vitro or animal research.
- Copper concentration can materially affect oxidative chemistry and assay results.
- FDA identifies limited human safety information and potential immunogenicity concerns for injectable compounded GHK-Cu.
Evidence trail